<?xml version="1.0" encoding="iso-8859-1"?>
<frameset>
<predicate lemma="lead">
<roleset id="lead.01" name="resulted
" wordnet="3">
<roles>
  <role n="0" descr="factors
"/>
  <role n="1" descr="result
"/>
</roles>
<example src="MEDLINE" no="1">
<text>
In this homologous part of the genes, GPB lacks one exon due to a point mutation at the 5&apos; splicing site of the third intron, which inactivates the 5&apos; cleavage event of splicing and leads to ligation of the second to the fourth exon.

</text>
       <arg n="0">a point mutation at the 5&apos; splicing site of the third intron
</arg>
       <arg n="1">ligation of the second to the fourth exon
</arg>
<fdg>
1	In	in	cla:&gt;10	@ADVL %EH PREP
2	this	this	det:&gt;4	@DN&gt; %&gt;N DET DEM SG
3	homologous	homologous	attr:&gt;4	@A&gt; %&gt;N A ABS
4	part	part	pcomp:&gt;1	@&lt;P %NH N NOM SG
5	of	of	mod:&gt;4	@&lt;NOM-OF %N&lt; PREP
6	the	the	det:&gt;7	@DN&gt; %&gt;N DET
7	genes	gene	pcomp:&gt;5	@&lt;P %NH N NOM PL
8	,	,
9	GPB	gpb	subj:&gt;10	@SUBJ %NH N NOM SG
10	lacks	lack	main:&gt;0	@+FMAINV %VA V PRES SG3
11	one	one	qn:&gt;12	@QN&gt; %&gt;N NUM CARD
12	exon	exon	obj:&gt;10	@OBJ %NH N NOM SG
13	due to	due to	ha:&gt;10	@ADVL %EH PREP
14	a	a	det:&gt;16	@DN&gt; %&gt;N DET SG
15	point	point	attr:&gt;16	@A&gt; %&gt;N N NOM SG
16	mutation	mutation	pcomp:&gt;13	@&lt;P %NH N NOM SG
17	at	at		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
18	the	the	det:&gt;19	@DN&gt; %&gt;N DET
19	5	5	pcomp:&gt;17	@&lt;P %NH NUM CARD
20	&apos;	&apos;
21	splicing	splice		@&lt;P-FMAINV %VA ING	@-FMAINV %VA ING
22	site	site	obj:&gt;21	@OBJ %NH N NOM SG
23	of	of	mod:&gt;22	@&lt;NOM-OF %N&lt; PREP
24	the	the	det:&gt;26	@DN&gt; %&gt;N DET
25	third	third	attr:&gt;26	@A&gt; %&gt;N NUM ORD
26	intron	intron	pcomp:&gt;23	@&lt;P %NH N NOM SG
27	,	,
28	which	which	subj:&gt;29	@SUBJ %NH &lt;Rel&gt; PRON WH NOM
29	inactivates	inactivate	mod:&gt;26	@+FMAINV %VA V PRES SG3
30	the	the	det:&gt;34	@DN&gt; %&gt;N DET
31	5	5	qn:&gt;34	@QN&gt; %&gt;N NUM CARD
32	&apos;	&apos;
33	cleavage	cleavage	attr:&gt;34	@A&gt; %&gt;N N NOM SG
34	event	event	obj:&gt;29	@OBJ %NH N NOM SG
35	of	of	mod:&gt;34	@&lt;NOM-OF %N&lt; PREP
36	splicing	splicing		@&lt;P %NH A ABS	@&lt;NOM %N&lt; A ABS	@&lt;P-FMAINV %VA ING
37	and	and	cc:&gt;29	@CC %CC CC
38	leads	lead	cc:&gt;29	@+FMAINV %VA V PRES SG3
39	to	to	ha:&gt;38	@ADVL %EH PREP
40	ligation	ligation	pcomp:&gt;39	@&lt;P %NH N NOM SG
41	of	of	mod:&gt;40	@&lt;NOM-OF %N&lt; PREP
42	the	the	det:&gt;43	@DN&gt; %&gt;N DET
43	second	second	pcomp:&gt;41	@&lt;P %NH NUM ORD
44	to	to		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
45	the	the	det:&gt;47	@DN&gt; %&gt;N DET
46	fourth	fourth	attr:&gt;47	@A&gt; %&gt;N NUM ORD
47	exon	exon	pcomp:&gt;44	@&lt;P %NH N NOM SG
48	.     .
</fdg>
</example>
<example src="MEDLINE" no="2">
<text>
We also studied in detail a complex splice site mutation, 3332dupl8bp, which was shown to lead to an abnormal JAG1 mRNA, resulting in a premature stop codon.

</text>
       <arg n="0">a complex splice site mutation
</arg>
       <arg n="1">an abnormal JAG1 mRNA, resulting in a premature stop codon
</arg>
<fdg>
1	We	we	subj:&gt;3	@SUBJ %NH PRON PERS NOM PL1
2	also	also	meta:&gt;3	@ADVL %EH ADV
3	studied	study	main:&gt;0	@+FMAINV %VA V PAST
4	in	in	loc:&gt;3	@ADVL %EH PREP
5	detail	detail	pcomp:&gt;4	@&lt;P %NH N NOM SG
6	a	a	det:&gt;10	@DN&gt; %&gt;N DET SG
7	complex	complex	attr:&gt;8	@A&gt; %&gt;N A ABS
8	splice	splice	attr:&gt;9	@A&gt; %&gt;N N NOM SG
9	site	site	attr:&gt;10	@A&gt; %&gt;N N NOM SG
10	mutation	mutation	obj:&gt;3	@OBJ %NH N NOM SG
11	,	,
12	3332dupl8bp	3332dupl8bp	mod:&gt;10	@APP %NH N NOM SG
13	,	,
14	which	which	subj:&gt;15	@SUBJ %NH &lt;Rel&gt; PRON WH NOM
15	was	be	mod:&gt;12	@+FMAINV %VA V PAST
16	shown	show		@-FMAINV %VP EN
17	to	to	pm:&gt;18	@INFMARK&gt; %AUX INFMARK&gt;
18	lead	lead	cnt:&gt;16	@-FMAINV %VA V INF
19	to	to	ha:&gt;18	@ADVL %EH PREP
20	an	an	det:&gt;22	@DN&gt; %&gt;N DET SG
21	abnormal	abnormal	attr:&gt;22	@A&gt; %&gt;N A ABS
22	JAG1	jag1	pcomp:&gt;19	@&lt;P %NH N NOM SG
23	mRNA	mrna	mod:&gt;22	@&lt;NOM %N&lt; ABBR NOM SG
24	,	,
25	resulting	result		@-FMAINV %VA ING
26	in	in	loc:&gt;25	@ADVL %EH PREP
27	a	a	det:&gt;30	@DN&gt; %&gt;N DET SG
28	premature	premature	attr:&gt;29	@A&gt; %&gt;N A ABS
29	stop	stop	attr:&gt;30	@A&gt; %&gt;N N NOM SG
30	codon	codon	pcomp:&gt;26	@&lt;P %NH N NOM SG
31	.     .
</fdg>
</example>
<example src="MEDLINE" no="3">
<text>
This patient&apos;s DNA contains a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele that is detectably expressed, leading to a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein.

</text>
       <arg n="0">a C----A transversion in the splice acceptor sequence of the last intron of the only ERCC-3 allele 
</arg>
       <arg n="1">a 4 bp insertion in the mRNA and an inactivating frameshift in the C-terminus of the protein
</arg>
<fdg>
1	This	this	det:&gt;3	@DN&gt; %&gt;N DET DEM SG
2	patient&apos;s	patient	attr:&gt;3	@A&gt; %&gt;N N GEN SG
3	DNA	dna	subj:&gt;4	@SUBJ %NH ABBR NOM SG
4	contains	contain	main:&gt;0	@+FMAINV %VA V PRES SG3
5	a	a	det:&gt;6	@DN&gt; %&gt;N DET SG
6	C	c	obj:&gt;4	@OBJ %NH N NOM SG
7	---	-	
8	-	-
9	A	a	det:&gt;10	@DN&gt; %&gt;N DET SG
10	transversion	transversion		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@APP %NH N NOM SG
11	in	in	mod:&gt;10	@&lt;NOM %N&lt; PREP
12	the	the	det:&gt;15	@DN&gt; %&gt;N DET
13	splice	splice	attr:&gt;14	@A&gt; %&gt;N N NOM SG
14	acceptor	acceptor	attr:&gt;15	@A&gt; %&gt;N N NOM SG
15	sequence	sequence	pcomp:&gt;11	@&lt;P %NH N NOM SG
16	of	of	mod:&gt;15	@&lt;NOM-OF %N&lt; PREP
17	the	the	det:&gt;19	@DN&gt; %&gt;N DET
18	last	last	attr:&gt;19	@DN&gt; %&gt;N DET
19	intron	intron	pcomp:&gt;16	@&lt;P %NH N NOM SG
20	of	of	mod:&gt;19	@&lt;NOM-OF %N&lt; PREP
21	the	the	det:&gt;24	@DN&gt; %&gt;N DET
22	only	only	attr:&gt;23	@A&gt; %&gt;N A ABS
23	ERCC-3	ercc-3	attr:&gt;24	@A&gt; %&gt;N N NOM SG
24	allele	allele	pcomp:&gt;20	@&lt;P %NH N NOM SG
25	that	that	subj:&gt;26	@SUBJ %NH &lt;Rel&gt; PRON
26	is	be	v-ch:&gt;28	@+FAUXV %AUX V PRES SG3
27	detectably	detectably	meta:&gt;28	@ADVL %EH ADV
28	expressed	express	mod:&gt;24	@-FMAINV %VP EN
29	,	,
30	leading	lead		@-FMAINV %VA ING
31	to	to	ha:&gt;30	@ADVL %EH PREP
32	a	a	det:&gt;33	@DN&gt; %&gt;N DET SG
33	4	4	pcomp:&gt;31	@&lt;P %NH NUM CARD
34	bp	bp	attr:&gt;35	@A&gt; %&gt;N ABBR NOM SG
35	insertion	insertion		@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG
36	in	in	mod:&gt;35	@&lt;NOM %N&lt; PREP
37	the	the	det:&gt;38	@DN&gt; %&gt;N DET
38	mRNA	mrna	pcomp:&gt;36	@&lt;P %NH ABBR NOM SG
39	and	and	cc:&gt;38	@CC %CC CC
40	an	an	det:&gt;42	@DN&gt; %&gt;N DET SG
41	inactivating	inactivating	attr:&gt;42	@A&gt; %&gt;N A ABS
42	frameshift	frameshift	cc:&gt;38	@&lt;P %NH &lt;?&gt; N NOM SG
43	in	in	mod:&gt;42	@&lt;NOM %N&lt; PREP
44	the	the	det:&gt;45	@DN&gt; %&gt;N DET
45	C-terminus	c-terminus	pcomp:&gt;43	@&lt;P %NH N NOM SG
46	of	of	mod:&gt;45	@&lt;NOM-OF %N&lt; PREP
47	the	the	det:&gt;48	@DN&gt; %&gt;N DET
48	protein	protein	pcomp:&gt;46	@&lt;P %NH N NOM SG
49	.     .
</fdg>
</example>
<example src="MEDLINE" no="4">
<text>
G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14 leads to a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S).

</text>
       <arg n="0">G979A affects a splice consensus site at the end of exon 8, and G1488T in exon 14
</arg>
       <arg n="1">a replacement of a positive charge in a highly conserved putative transmembrane domain (R496S)
</arg>
<fdg>

1	G979A	g979a	subj:&gt;2	@SUBJ %NH N NOM SG
2	affects	affect	main:&gt;0	@+FMAINV %VA V PRES SG3
3	a	a	det:&gt;6	@DN&gt; %&gt;N DET SG
4	splice	splice	attr:&gt;5	@A&gt; %&gt;N N NOM SG
5	consensus	consensus	attr:&gt;6	@A&gt; %&gt;N N NOM SG
6	site	site	obj:&gt;2	@OBJ %NH N NOM SG
7	at	at	loc:&gt;2	@ADVL %EH PREP
8	the	the	det:&gt;9	@DN&gt; %&gt;N DET
9	end	end	pcomp:&gt;7	@&lt;P %NH N NOM SG
10	of	of	mod:&gt;9	@&lt;NOM-OF %N&lt; PREP
11	exon	exon	attr:&gt;12	@A&gt; %&gt;N N NOM SG
12	8	8	pcomp:&gt;10	@&lt;P %NH NUM CARD
13	,	,
14	and	and	cc:&gt;12	@CC %CC CC
15	G1488T	g1488t	cc:&gt;12	@&lt;P %NH N NOM SG
16	in	in	mod:&gt;15	@&lt;NOM %N&lt; PREP
17	exon	exon	pcomp:&gt;16	@&lt;P %NH N NOM SG
18	14	14	qn:&gt;19	@QN&gt; %&gt;N NUM CARD
19	leads	lead		@SUBJ %NH N NOM PL
20	to	to		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
21	a	a	det:&gt;22	@DN&gt; %&gt;N DET SG
22	replacement	replacement	pcomp:&gt;20	@&lt;P %NH N NOM SG
23	of	of	mod:&gt;22	@&lt;NOM-OF %N&lt; PREP
24	a	a	det:&gt;26	@DN&gt; %&gt;N DET SG
25	positive	positive	attr:&gt;26	@A&gt; %&gt;N A ABS
26	charge	charge	pcomp:&gt;23	@&lt;P %NH N NOM SG
27	in	in		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
28	a	a		@DN&gt; %&gt;N DET SG
29	highly	highly	ad:&gt;30	@AD-A&gt; %E&gt; ADV
30	conserved	conserved	attr:&gt;31	@A&gt; %&gt;N A ABS
31	putative	putative	attr:&gt;32	@A&gt; %&gt;N A ABS
32	transmembrane	transmembrane	attr:&gt;33	@A&gt; %&gt;N &lt;?&gt; N NOM SG
33	domain	domain		@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
34	(	(
35	R496S)	r496s)		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@APP %NH N NOM SG	@&lt;P %NH N NOM SG
36	.     .
</fdg>
</example>
<example src="MEDLINE" no="5">
<text>
By direct sequencing of aberrant SSCA conformers were revealed 15 different mutations in a total of 18 unrelated families and 13 single patients. Of these, 10 were novel (7 missense mutations, 2 mutations leading to frameshift, and 1 mutation predicted to affect normal splicing).

</text>
       <arg n="0">7 missense mutations, 2 mutations
</arg>
       <arg n="1">frameshift
</arg>
<fdg>
1	By	by	cla:&gt;9	@ADVL %EH PREP
2	direct	direct	attr:&gt;3	@A&gt; %&gt;N A ABS
3	sequencing	sequencing	pcomp:&gt;1	@&lt;P %NH N NOM SG
4	of	of	mod:&gt;3	@&lt;NOM-OF %N&lt; PREP
5	aberrant	aberrant	attr:&gt;6	@A&gt; %&gt;N A ABS
6	SSCA	ssca	attr:&gt;7	@A&gt; %&gt;N N NOM SG
7	conformers	conformer	subj:&gt;8	@SUBJ %NH N NOM PL
8	were	be	v-ch:&gt;9	@+FAUXV %AUX V PAST PL
9	revealed	reveal	main:&gt;0	@-FMAINV %VP EN
10	15	15	qn:&gt;12	@QN&gt; %&gt;N NUM CARD
11	different	different	attr:&gt;12	@A&gt; %&gt;N A ABS
12	mutations	mutation		@SUBJ %NH N NOM PL
13	in	in	ha:&gt;9	@ADVL %EH PREP
14	a	a	det:&gt;15	@DN&gt; %&gt;N DET SG
15	total	total	pcomp:&gt;13	@&lt;P %NH A ABS
16	of	of	mod:&gt;15	@&lt;NOM-OF %N&lt; PREP
17	18	18	qn:&gt;19	@QN&gt; %&gt;N NUM CARD
18	unrelated	unrelated	attr:&gt;19	@A&gt; %&gt;N A ABS
19	families	family	pcomp:&gt;16	@&lt;P %NH N NOM PL
20	and	and	cc:&gt;19	@CC %CC CC
21	13	13	qn:&gt;23	@QN&gt; %&gt;N NUM CARD
22	single	single	attr:&gt;23	@A&gt; %&gt;N A ABS
23	patients	patient	cc:&gt;19	@&lt;P %NH N NOM PL
24	.     .
</fdg>
</example>
<example src="MEDLINE" no="6">
<text>
Disruption of the SNU246 gene in yeast is lethal and leads to a splicing defect in vivo, indicating that the protein is essential for splicing.

</text>
       <arg n="0">Disruption of the SNU246 gene in yeast
</arg>
       <arg n="1">a splicing defect in vivo, indicating that the protein is essential for splicing
</arg>
<fdg>
1	Disruption	disruption	subj:&gt;8	@SUBJ %NH N NOM SG
2	of	of	mod:&gt;1	@&lt;NOM-OF %N&lt; PREP
3	the	the	det:&gt;5	@DN&gt; %&gt;N DET
4	SNU246	snu246	attr:&gt;5	@A&gt; %&gt;N N NOM SG
5	gene	gene	pcomp:&gt;2	@&lt;P %NH N NOM SG
6	in	in	mod:&gt;5	@&lt;NOM %N&lt; PREP
7	yeast	yeast	pcomp:&gt;6	@&lt;P %NH N NOM SG
8	is	be	main:&gt;0	@+FMAINV %VA V PRES SG3
9	lethal	lethal	comp:&gt;8	@PCOMPL-S %NH A ABS
10	and	and	cc:&gt;8	@CC %CC CC
11	leads	lead	cc:&gt;8	@+FMAINV %VA V PRES SG3
12	to	to	ha:&gt;11	@ADVL %EH PREP
13	a	a		@DN&gt; %&gt;N DET SG
14	splicing	splicing	attr:&gt;15	@A&gt; %&gt;N A ABS
15	defect	defect	attr:&gt;16	@A&gt; %&gt;N N NOM SG
16	in vivo	in vivo		@A&gt; %&gt;N A ABS
17	,	,
18	indicating	indicate	man:&gt;11	@-FMAINV %VA ING
19	that	that	pm:&gt;22	@CS %CS CS
20	the	the	det:&gt;21	@DN&gt; %&gt;N DET
21	protein	protein	subj:&gt;22	@SUBJ %NH N NOM SG
22	is	be	obj:&gt;18	@+FMAINV %VA V PRES SG3
23	essential	essential	comp:&gt;22	@PCOMPL-S %NH A ABS
24	for	for	mod:&gt;23	@&lt;NOM %N&lt; PREP
25	splicing	splicing	pcomp:&gt;24	@&lt;P %NH A ABS
26	.     .
</fdg>
</example>
<example src="MEDLINE" no="7">
<text>
The mutations identified include: two frameshifts and a splice site mutation leading to truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations, two of which involve amino acids located within putative transmembrane domains.

</text>
       <arg n="0">two frameshifts and a splice site mutation
</arg>
       <arg n="1">truncated OA1 proteins; a deletion of a threonine codon at position 290; and four missense mutations 
</arg>
<fdg>

1	The	the	det:&gt;2	@DN&gt; %&gt;N DET
2	mutations	mutation	subj:&gt;4	@SUBJ %NH N NOM PL
3	identified	identify	mod:&gt;2	@-FMAINV %VP EN
4	include	include	main:&gt;0	@+FMAINV %VA V PRES
5	:	:
6	two	two	qn:&gt;7	@QN&gt; %&gt;N NUM CARD
7	frameshifts	frameshift		@NH %NH &lt;?&gt; N NOM PL	@SUBJ %NH &lt;?&gt; N NOM PL	@OBJ %NH &lt;?&gt; N NOM PL
8	and	and	cc:&gt;7	@CC %CC CC
9	a	a	det:&gt;12	@DN&gt; %&gt;N DET SG
10	splice	splice	attr:&gt;11	@A&gt; %&gt;N N NOM SG
11	site	site	attr:&gt;12	@A&gt; %&gt;N N NOM SG
12	mutation	mutation	cc:&gt;7	@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG
13	leading	lead	mod:&gt;12	@-FMAINV %VA ING
14	to	to	ha:&gt;13	@ADVL %EH PREP
15	truncated	truncated	attr:&gt;16	@A&gt; %&gt;N A ABS
16	OA1	oa1	attr:&gt;17	@A&gt; %&gt;N N NOM SG
17	proteins	protein	pcomp:&gt;14	@&lt;P %NH N NOM PL
18	;	;
19	a	a	det:&gt;20	@DN&gt; %&gt;N DET SG
20	deletion	deletion		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG
21	of	of	mod:&gt;20	@&lt;NOM-OF %N&lt; PREP
22	a	a	det:&gt;24	@DN&gt; %&gt;N DET SG
23	threonine	threonine	attr:&gt;24	@A&gt; %&gt;N &lt;?&gt; N NOM SG
24	codon	codon	pcomp:&gt;21	@&lt;P %NH N NOM SG
25	at	at		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
26	position	position	attr:&gt;27	@A&gt; %&gt;N N NOM SG
27	290	290	pcomp:&gt;25	@&lt;P %NH NUM CARD
28	;	;
29	and	and	cc:&gt;28	@CC %CC CC
30	four	four	qn:&gt;32	@QN&gt; %&gt;N NUM CARD
31	missense	missense	attr:&gt;32	@A&gt; %&gt;N &lt;?&gt; N NOM SG
32	mutations	mutation		@NH %NH N NOM PL	@SUBJ %NH N NOM PL	@OBJ %NH N NOM PL	@&lt;P %NH N NOM PL
33	,	,
34	two	two	subj:&gt;37	@SUBJ %NH NUM CARD
35	of	of	mod:&gt;34	@&lt;NOM-OF %N&lt; PREP
36	which	which	pcomp:&gt;35	@&lt;P %NH &lt;Rel&gt; PRON WH NOM
37	involve	involve	cc:&gt;13	@+FMAINV %VA V PRES
38	amino	amino	attr:&gt;39	@A&gt; %&gt;N N NOM SG
39	acids	acid	obj:&gt;37	@OBJ %NH N NOM PL
40	located	locate	mod:&gt;39	@-FMAINV %VP EN
41	within	within	ha:&gt;40	@ADVL %EH PREP
42	putative	putative	attr:&gt;43	@A&gt; %&gt;N A ABS
43	transmembrane	transmembrane	attr:&gt;44	@A&gt; %&gt;N &lt;?&gt; N NOM SG
44	domains	domain	pcomp:&gt;41	@&lt;P %NH N NOM PL
45	.     .
</fdg>
</example>
<example src="MEDLINE" no="8">
<text>
This was caused by a point mutation (GTC----ATC) at codon 383, which leads to the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter.

</text>
       <arg n="0">a point mutation (GTC----ATC) at codon 383
</arg>
       <arg n="1">the conservative substitution of isoleucine for valine in the putative fifth extracellular loop of the transporter
</arg>
<fdg>

1	This	this	subj:&gt;2	@SUBJ %NH PRON DEM SG
2	was	be	v-ch:&gt;3	@+FAUXV %AUX V PAST
3	caused	cause	main:&gt;0	@-FMAINV %VP EN
4	by	by	ha:&gt;3	@ADVL %EH PREP
5	a	a	det:&gt;7	@DN&gt; %&gt;N DET SG
6	point	point	attr:&gt;7	@A&gt; %&gt;N N NOM SG
7	mutation	mutation	pcomp:&gt;4	@&lt;P %NH N NOM SG
8	(	(
9	GTC	gtc		@NH %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG
10	---	-	
11	-	-
12	&lt;s&gt;	&lt;s&gt;
1	ATC	atc		@NH %NH ABBR NOM SG
2	)	)
3	at	at		@ADVL %EH PREP
4	codon	codon	attr:&gt;5	@A&gt; %&gt;N N NOM SG
5	383	383	pcomp:&gt;3	@&lt;P %NH NUM CARD
6	,	,
7	which	which	subj:&gt;8	@SUBJ %NH &lt;Rel&gt; PRON WH NOM
8	leads	lead	mod:&gt;5	@+FMAINV %VA V PRES SG3
9	to	to	ha:&gt;8	@ADVL %EH PREP
10	the	the	det:&gt;12	@DN&gt; %&gt;N DET
11	conservative	conservative	attr:&gt;12	@A&gt; %&gt;N A ABS
12	substitution	substitution	pcomp:&gt;9	@&lt;P %NH N NOM SG
13	of	of	mod:&gt;12	@&lt;NOM-OF %N&lt; PREP
14	isoleucine	isoleucine	pcomp:&gt;13	@&lt;P %NH &lt;?&gt; N NOM SG
15	for	for	mod:&gt;14	@&lt;NOM %N&lt; PREP
16	valine	valine	pcomp:&gt;15	@&lt;P %NH &lt;?&gt; N NOM SG
17	in	in	mod:&gt;16	@&lt;NOM %N&lt; PREP
18	the	the	det:&gt;22	@DN&gt; %&gt;N DET
19	putative	putative	attr:&gt;20	@A&gt; %&gt;N A ABS
20	fifth	fifth	attr:&gt;21	@A&gt; %&gt;N NUM ORD
21	extracellular	extracellular	attr:&gt;22	@A&gt; %&gt;N A ABS
22	loop	loop	pcomp:&gt;17	@&lt;P %NH N NOM SG
23	of	of	mod:&gt;22	@&lt;NOM-OF %N&lt; PREP
24	the	the	det:&gt;25	@DN&gt; %&gt;N DET
25	transporter	transporter	pcomp:&gt;23	@&lt;P %NH N NOM SG
26	.     .
</fdg>
</example>
<example src="MEDLINE" no="9">
<text>
Genetic deficiency of GM2 activator leads to a neurological disorder, an atypical form of Tay-Sachs disease (GM2 gangliosidosis variant AB).

</text>
       <arg n="0">Genetic deficiency of GM2 activator
</arg>
       <arg n="1">a neurological disorder
</arg>
<fdg>
1	Genetic	genetic	attr:&gt;2	@A&gt; %&gt;N A ABS
2	deficiency	deficiency	subj:&gt;6	@SUBJ %NH N NOM SG
3	of	of	mod:&gt;2	@&lt;NOM-OF %N&lt; PREP
4	GM2	gm2	attr:&gt;5	@A&gt; %&gt;N N NOM SG
5	activator	activator	pcomp:&gt;3	@&lt;P %NH N NOM SG
6	leads	lead	main:&gt;0	@+FMAINV %VA V PRES SG3
7	to	to	ha:&gt;6	@ADVL %EH PREP
8	a	a	det:&gt;10	@DN&gt; %&gt;N DET SG
9	neurological	neurological	attr:&gt;10	@A&gt; %&gt;N A ABS
10	disorder	disorder	pcomp:&gt;7	@&lt;P %NH N NOM SG
11	,	,
12	an	an	det:&gt;14	@DN&gt; %&gt;N DET SG
13	atypical	atypical	attr:&gt;14	@A&gt; %&gt;N A ABS
14	form	form	mod:&gt;10	@APP %NH N NOM SG
15	of	of	mod:&gt;14	@&lt;NOM-OF %N&lt; PREP
16	Tay-Sachs	tay-#sachs	attr:&gt;17	@A&gt; %&gt;N N NOM SG
17	disease	disease	pcomp:&gt;15	@&lt;P %NH N NOM SG
18	(	(
19	GM2	gm2	attr:&gt;20	@A&gt; %&gt;N N NOM SG
20	gangliosidosis	gangliosidosis	attr:&gt;21	@A&gt; %&gt;N &lt;?&gt; N NOM
21	variant	variant	attr:&gt;22	@A&gt; %&gt;N N NOM SG
22	AB	ab		@APP %NH ABBR NOM SG	@A&gt; %&gt;N ABBR NOM SG	@NH %NH ABBR NOM SG
23	)	)
24	.     .
</fdg>
</example>
<example src="MEDLINE" no="10">
<text>
These results suggest that the distinct amino termini lead to the targeting of individual VDAC isoforms to different cellular compartments.

</text>
       <arg n="0">the distinct amino termini
</arg>
       <arg n="1">the targeting of individual VDAC isoforms to different cellular compartments
</arg>
<fdg>
1	These	this	det:&gt;2	@DN&gt; %&gt;N DET DEM PL
2	results	result	subj:&gt;3	@SUBJ %NH N NOM PL
3	suggest	suggest	main:&gt;0	@+FMAINV %VA V PRES
4	that	that	pm:&gt;9	@CS %CS CS
5	the	the	det:&gt;8	@DN&gt; %&gt;N DET
6	distinct	distinct	attr:&gt;7	@A&gt; %&gt;N A ABS
7	amino	amino	attr:&gt;8	@A&gt; %&gt;N N NOM SG
8	termini	terminus	subj:&gt;9	@SUBJ %NH N NOM PL
9	lead	lead	obj:&gt;3	@+FMAINV %VA V PRES
10	to	to	ha:&gt;9	@ADVL %EH PREP
11	the	the	det:&gt;12	@DN&gt; %&gt;N DET
12	targeting	targeting	pcomp:&gt;10	@&lt;P %NH A ABS
13	of	of	mod:&gt;12	@&lt;NOM-OF %N&lt; PREP
14	individual	individual	attr:&gt;15	@A&gt; %&gt;N A ABS
15	VDAC	vdac	attr:&gt;16	@A&gt; %&gt;N N NOM SG
16	isoforms	isoform	pcomp:&gt;13	@&lt;P %NH &lt;?&gt; N NOM PL
17	to	to		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
18	different	different	attr:&gt;19	@A&gt; %&gt;N A ABS
19	cellular	cellular	attr:&gt;20	@A&gt; %&gt;N A ABS
20	compartments	compartment	pcomp:&gt;17	@&lt;P %NH N NOM PL
21	.     .
</fdg>
</example>
<example src="MEDLINE" no="11">
<text>
This splice mutation in 5 end of intron 5 might lead to abnormal splice in exon 5 and exon 6 and bring about unstable and abnormal ALD protein; the lignoceryl CoA ligase could not transport very long chain fatty acids (VLCFA) into peroxisome and could not function normally; consequently, defective beta-oxidation of VLCFA in peroxisome could result in an accumulation of VLCFAS in the central nervous system, adrenal gland and blood.

</text>
       <arg n="0">This splice mutation in 5 end of intron 5
</arg>
       <arg n="1">abnormal splice in exon 5 and exon 6
</arg>
<fdg>
1	This	this	det:&gt;3	@DN&gt; %&gt;N DET DEM SG
2	splice	splice	attr:&gt;3	@A&gt; %&gt;N N NOM SG
3	mutation	mutation	main:&gt;0	@NH %NH N NOM SG
4	in	in	mod:&gt;3	@&lt;NOM %N&lt; PREP
5	5	5	pcomp:&gt;4	@&lt;P %NH NUM CARD
6	&apos;	&apos;
7	end	end	subj:&gt;11	@SUBJ %NH N NOM SG
8	of	of	mod:&gt;7	@&lt;NOM-OF %N&lt; PREP
9	intron	intron	attr:&gt;10	@A&gt; %&gt;N N NOM SG
10	5	5	pcomp:&gt;8	@&lt;P %NH NUM CARD
11	might	might	v-ch:&gt;12	@+FAUXV %AUX V AUXMOD
12	lead	lead		@-FMAINV %VA V INF
13	to	to	ha:&gt;12	@ADVL %EH PREP
14	abnormal	abnormal	attr:&gt;15	@A&gt; %&gt;N A ABS
15	splice	splice	pcomp:&gt;13	@&lt;P %NH N NOM SG
16	in	in	mod:&gt;15	@&lt;NOM %N&lt; PREP
17	exon	exon	attr:&gt;18	@A&gt; %&gt;N N NOM SG
18	5	5	pcomp:&gt;16	@&lt;P %NH NUM CARD
19	and	and		@CC %CC CC
20	exon	exon	attr:&gt;21	@A&gt; %&gt;N N NOM SG
21	6	6		@SUBJ %NH NUM CARD	@OBJ %NH NUM CARD	@&lt;P %NH NUM CARD
22	and	and	cc:&gt;12	@CC %CC CC
23	bring	bring	cc:&gt;12	@-FMAINV %VA V INF
24	about	about	ad:&gt;25	@AD-A&gt; %E&gt; ADV
25	unstable	unstable	cc:&gt;27	@A&gt; %&gt;N A ABS
26	and	and	cc:&gt;27	@CC %CC CC
27	abnormal	abnormal	attr:&gt;28	@A&gt; %&gt;N A ABS
28	ALD	ald	attr:&gt;29	@A&gt; %&gt;N N NOM SG
29	protein	protein	obj:&gt;23	@OBJ %NH N NOM SG
30	;	;
31	the	the	det:&gt;34	@DN&gt; %&gt;N DET
32	lignoceryl	lignoceryl	attr:&gt;33	@A&gt; %&gt;N &lt;?&gt; N NOM SG
33	CoA	coa	attr:&gt;34	@A&gt; %&gt;N N NOM SG
34	ligase	ligase	subj:&gt;35	@SUBJ %NH &lt;?&gt; N NOM SG
35	could	could	v-ch:&gt;37	@+FAUXV %AUX V AUXMOD
36	not	not	neg:&gt;35	@ADVL %EH NEG-PART
37	transport	transport	cc:&gt;23	@-FMAINV %VA V INF
38	very	very	ad:&gt;39	@AD-A&gt; %E&gt; ADV
39	long	long	attr:&gt;40	@A&gt; %&gt;N A ABS
40	chain	chain	attr:&gt;41	@A&gt; %&gt;N N NOM SG
41	fatty	fatty	attr:&gt;42	@A&gt; %&gt;N A ABS
42	acids	acid	obj:&gt;37	@OBJ %NH N NOM PL
43	(	(
44	VLCFA	vlcfa	mod:&gt;42	@NH %NH N NOM SG
45	)	)
46	into	into	goa:&gt;37	@ADVL %EH PREP
47	peroxisome	peroxisome	pcomp:&gt;46	@&lt;P %NH &lt;?&gt; N NOM SG
48	and	and	cc:&gt;37	@CC %CC CC
49	could	could	v-ch:&gt;51	@+FAUXV %AUX V AUXMOD
50	not	not	neg:&gt;49	@ADVL %EH NEG-PART
51	function	function	cc:&gt;37	@-FMAINV %VA V INF
52	normally	normally	man:&gt;51	@ADVL %EH ADV
53	;	;
54	consequently	consequently		@ADVL %EH ADV	@AD-A&gt; %E&gt; ADV
55	,	,
56	defective	defective	attr:&gt;57	@A&gt; %&gt;N A ABS
57	beta-oxidation	beta-oxidation	subj:&gt;62	@SUBJ %NH &lt;?&gt; N NOM SG
58	of	of	mod:&gt;57	@&lt;NOM-OF %N&lt; PREP
59	VLCFA	vlcfa	pcomp:&gt;58	@&lt;P %NH N NOM SG
60	in	in	mod:&gt;59	@&lt;NOM %N&lt; PREP
61	peroxisome	peroxisome	pcomp:&gt;60	@&lt;P %NH &lt;?&gt; N NOM SG
62	could	could	v-ch:&gt;63	@+FAUXV %AUX V AUXMOD
63	result	result	cc:&gt;51	@-FMAINV %VA V INF
64	in	in	loc:&gt;63	@ADVL %EH PREP
65	an	an	det:&gt;66	@DN&gt; %&gt;N DET SG
66	accumulation	accumulation	pcomp:&gt;64	@&lt;P %NH N NOM SG
67	of	of	mod:&gt;66	@&lt;NOM-OF %N&lt; PREP
68	VLCFAS	vlcfas	pcomp:&gt;67	@&lt;P %NH N NOM SG
69	in	in	phr:&gt;63	@ADVL %EH PREP
70	the	the	det:&gt;73	@DN&gt; %&gt;N DET
71	central	central	attr:&gt;72	@A&gt; %&gt;N A ABS
72	nervous	nervous	attr:&gt;73	@A&gt; %&gt;N A ABS
73	system	system	pcomp:&gt;69	@&lt;P %NH N NOM SG
74	,	,
75	adrenal	adrenal	attr:&gt;76	@A&gt; %&gt;N A ABS
76	gland	gland	cc:&gt;73	@&lt;P %NH N NOM SG
77	and	and	cc:&gt;76	@CC %CC CC
78	blood	blood	cc:&gt;76	@&lt;P %NH N NOM SG
79	.     .
</fdg>
</example>
<example src="MEDLINE" no="12">
<text>
The splice mutation in 5 end of intron 5 leading to abnormal splice in exon 5 and exon 6 appears to be one of the causes of X-linked recessive adrenoleukodystrophy.

</text>
       <arg n="0">The splice mutation in 5 end of intron 5
</arg>
       <arg n="1">abnormal splice in exon 5 and exon 6
</arg>
<fdg>
3	The	the	det:&gt;5	@DN&gt; %&gt;N DET
4	splice	splice	attr:&gt;5	@A&gt; %&gt;N N NOM SG
5	mutation	mutation	main:&gt;2	@NH %NH N NOM SG
6	in	in	mod:&gt;5	@&lt;NOM %N&lt; PREP
7	5	5	pcomp:&gt;6	@&lt;P %NH NUM CARD
8	&apos;	&apos;
9	end	end		@NH %NH N NOM SG	@SUBJ %NH N NOM SG
10	of	of	mod:&gt;9	@&lt;NOM-OF %N&lt; PREP
11	intron	intron	pcomp:&gt;10	@&lt;P %NH N NOM SG
12	5	5		@QN&gt; %&gt;N NUM CARD
13	leading	lead		@&lt;P-FMAINV %VA ING	@-FMAINV %VA ING
14	to	to	ha:&gt;13	@ADVL %EH PREP
15	abnormal	abnormal	attr:&gt;16	@A&gt; %&gt;N A ABS
16	splice	splice	pcomp:&gt;14	@&lt;P %NH N NOM SG
17	in	in	mod:&gt;16	@&lt;NOM %N&lt; PREP
18	exon	exon	attr:&gt;19	@A&gt; %&gt;N N NOM SG
19	5	5	pcomp:&gt;17	@&lt;P %NH NUM CARD
20	and	and		@CC %CC CC
21	exon	exon	subj:&gt;23	@SUBJ %NH N NOM SG
22	6	6	mod:&gt;21	@&lt;NOM %N&lt; NUM CARD
23	appears	appear		@+FMAINV %VA V PRES SG3
24	to	to	pm:&gt;25	@INFMARK&gt; %AUX INFMARK&gt;
25	be	be	comp:&gt;23	@-FMAINV %VA V INF
26	one	one	comp:&gt;25	@PCOMPL-S %NH NUM CARD
27	of	of	mod:&gt;26	@&lt;NOM-OF %N&lt; PREP
28	the	the	det:&gt;29	@DN&gt; %&gt;N DET
29	causes	cause	pcomp:&gt;27	@&lt;P %NH N NOM PL
30	of	of	mod:&gt;29	@&lt;NOM-OF %N&lt; PREP
31	X-linked	x-linked	attr:&gt;32	@A&gt; %&gt;N A ABS
32	recessive	recessive	attr:&gt;33	@A&gt; %&gt;N A ABS
33	adrenoleukodystrophy	adrenoleukodystrophy	pcomp:&gt;30	@&lt;P %NH &lt;?&gt; N NOM SG
34	.     .
</fdg>
</example>
<example src="MEDLINE" no="13">
<text>
This leads to a substantial diversity of nebulin and nebulette isoforms.

</text>
       <arg n="0">This
</arg>
       <arg n="1">a substantial diversity of nebulin and nebulette isoforms
</arg>
<fdg>
1	This	this	subj:&gt;2	@SUBJ %NH PRON DEM SG
2	leads	lead	main:&gt;0	@+FMAINV %VA V PRES SG3
3	to	to	ha:&gt;2	@ADVL %EH PREP
4	a	a	det:&gt;6	@DN&gt; %&gt;N DET SG
5	substantial	substantial	attr:&gt;6	@A&gt; %&gt;N A ABS
6	diversity	diversity	pcomp:&gt;3	@&lt;P %NH N NOM SG
7	of	of	mod:&gt;6	@&lt;NOM-OF %N&lt; PREP
8	nebulin	nebulin	cc:&gt;10	@A&gt; %&gt;N &lt;?&gt; N NOM SG
9	and	and	cc:&gt;10	@CC %CC CC
10	nebulette	nebulette	attr:&gt;11	@A&gt; %&gt;N &lt;?&gt; N NOM SG
11	isoforms	isoform	pcomp:&gt;7	@&lt;P %NH &lt;?&gt; N NOM PL
12	.     .
</fdg>
</example>
<example src="EMBO" no="1">
<text>
In mice, inactivation of the MEF2C gene, which is the first MEF2 isoform expressed during embryonic development, leads to cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5 (Lin et al., 1997, 1998; Bi et al., 1999).

</text>
       <arg n="0">inactivation of the MEF2C gene
</arg>
       <arg n="1">cardiac morphogenetic defects, vascular abnormalities and lethality by embryonic day 9.5
</arg>
<fdg>
1	In	in	cla:&gt;21	@ADVL %EH PREP
2	mice	mouse	pcomp:&gt;1	@&lt;P %NH N NOM PL
3	,	,
4	inactivation	inactivation	subj:&gt;21	@SUBJ %NH N NOM SG
5	of	of	mod:&gt;4	@&lt;NOM-OF %N&lt; PREP
6	the	the	det:&gt;8	@DN&gt; %&gt;N DET
7	MEF2C	mef2c	attr:&gt;8	@A&gt; %&gt;N N NOM SG
8	gene	gene	pcomp:&gt;5	@&lt;P %NH N NOM SG
9	,	,
10	which	which		@SUBJ %NH &lt;Rel&gt; PRON WH NOM
11	is	be	v-ch:&gt;16	@+FAUXV %AUX V PRES SG3
12	the	the	det:&gt;15	@DN&gt; %&gt;N DET
13	first	first	attr:&gt;14	@A&gt; %&gt;N NUM ORD
14	MEF2	mef2	attr:&gt;15	@A&gt; %&gt;N N NOM SG
15	isoform	isoform	subj:&gt;11	@SUBJ %NH &lt;?&gt; N NOM SG
16	expressed	express	mod:&gt;8	@-FMAINV %VP EN
17	during	during	ha:&gt;16	@ADVL %EH PREP
18	embryonic	embryonic	attr:&gt;19	@A&gt; %&gt;N A ABS
19	development	development	pcomp:&gt;17	@&lt;P %NH N NOM SG
20	,	,
21	leads	lead	main:&gt;0	@+FMAINV %VA V PRES SG3
22	to	to	ha:&gt;21	@ADVL %EH PREP
23	cardiac	cardiac	attr:&gt;24	@A&gt; %&gt;N A ABS
24	morphogenetic	morphogenetic	attr:&gt;25	@A&gt; %&gt;N A ABS
25	defects	defect	pcomp:&gt;22	@&lt;P %NH N NOM PL
26	,	,
27	vascular	vascular	attr:&gt;28	@A&gt; %&gt;N A ABS
28	abnormalities	abnormality	cc:&gt;25	@&lt;P %NH N NOM PL
29	and	and	cc:&gt;28	@CC %CC CC
30	lethality	lethality	cc:&gt;28	@&lt;P %NH N NOM SG
31	by	by		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
32	embryonic	embryonic	attr:&gt;33	@A&gt; %&gt;N A ABS
33	day	day	pcomp:&gt;31	@&lt;P %NH N NOM SG
34	9.5	9.5	mod:&gt;33	@&lt;NOM %N&lt; NUM CARD
35	(	(
36	Lin	lin	main:&gt;35	@APP %NH N NOM SG
37	et	et	cc:&gt;36	@CC %CC CC
38	al.	al.	cc:&gt;36	@APP %NH ABBR NOM SG
39	,	,
40	1997	1997		@ADVL %EH NUM CARD
41	,	,
42	1998	1998		@NH %NH NUM CARD	@&lt;P %NH NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
43	;	;
44	Bi	bi	main:&gt;43	@NH %NH N NOM SG
45	et	et	cc:&gt;44	@CC %CC CC
46	al.	al.	cc:&gt;44	@NH %NH ABBR NOM SG
47	,	,
48	1999	1999	cc:&gt;46	@NH %NH NUM CARD
49	)	)
50	.     .
</fdg>
</example>
<example src="EMBO" no="2">
<text>
Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D leads to a synergistic 40-to 50-fold activation of the ANF promoter (Figure 3A).

</text>
       <arg n="0">Cotransfection of GATA-4 with MEF2A, MEF2C or MEF2D
</arg>
       <arg n="1">a synergistic 40-to 50-fold activation of the ANF promoter
</arg>
<fdg>
1	Cotransfection	cotransfection	subj:&gt;10	@SUBJ %NH &lt;?&gt; N NOM SG
2	of	of	mod:&gt;1	@&lt;NOM-OF %N&lt; PREP
3	GATA-4	gata-4	pcomp:&gt;2	@&lt;P %NH N NOM SG
4	with	with	mod:&gt;3	@&lt;NOM %N&lt; PREP
5	MEF2A	mef2a	pcomp:&gt;4	@&lt;P %NH N NOM SG
6	,	,
7	MEF2C	mef2c	cc:&gt;5	@&lt;P %NH N NOM SG
8	or	or	cc:&gt;7	@CC %CC CC
9	MEF2D	mef2d	cc:&gt;7	@&lt;P %NH N NOM SG
10	leads	lead	main:&gt;0	@+FMAINV %VA V PRES SG3
11	to	to	ha:&gt;10	@ADVL %EH PREP
12	a	a	det:&gt;14	@DN&gt; %&gt;N DET SG
13	synergistic	synergistic	attr:&gt;14	@A&gt; %&gt;N A ABS
14	40-	40-	pcomp:&gt;11	@&lt;P %NH NUM CARD
15	to	to		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
16	50-fold	50-fold	attr:&gt;17	@A&gt; %&gt;N A ABS
17	activation	activation	pcomp:&gt;15	@&lt;P %NH N NOM SG
18	of	of	mod:&gt;17	@&lt;NOM-OF %N&lt; PREP
19	the	the	det:&gt;21	@DN&gt; %&gt;N DET
20	ANF	anf	attr:&gt;21	@A&gt; %&gt;N N NOM SG
21	promoter	promoter	pcomp:&gt;18	@&lt;P %NH N NOM SG
22	(	(
23	Figure	figure	attr:&gt;24	@A&gt; %&gt;N N NOM SG
24	3A	3a		@NH %NH NUM CARD	@APP %NH NUM CARD	@A&gt; %&gt;N NUM CARD
25	)	)
26	.     .
</fdg>
</example>
<example src="EMBO" no="3">
<text>
This, in turn, leads to synergistic activation of the ANF and other MEF2 target promoters independently of the DNA-binding activity of MEF2.

</text>
       <arg n="0">This
</arg>
       <arg n="1">synergistic activation of the ANF and other MEF2 target promoters
</arg>
<fdg>
1	This	this	subj:&gt;6	@SUBJ %NH PRON DEM SG
2	,	,
3	in	in	mod:&gt;1	@ADVL %EH PREP
4	turn	turn	pcomp:&gt;3	@&lt;P %NH N NOM SG
5	,	,
6	leads	lead	main:&gt;0	@+FMAINV %VA V PRES SG3
7	to	to	ha:&gt;6	@ADVL %EH PREP
8	synergistic	synergistic	attr:&gt;9	@A&gt; %&gt;N A ABS
9	activation	activation	pcomp:&gt;7	@&lt;P %NH N NOM SG
10	of	of	mod:&gt;9	@&lt;NOM-OF %N&lt; PREP
11	the	the	det:&gt;12	@DN&gt; %&gt;N DET
12	ANF	anf	pcomp:&gt;10	@&lt;P %NH N NOM SG
13	and	and	cc:&gt;6	@CC %CC CC
14	other	other	det:&gt;15	@DN&gt; %&gt;N DET
15	MEF2	mef2	subj:&gt;16	@SUBJ %NH N NOM SG
16	target	target	cc:&gt;6	@+FMAINV %VA V PRES
17	promoters	promoter	obj:&gt;16	@OBJ %NH N NOM PL
18	independently	independently	man:&gt;16	@ADVL %EH ADV
19	of	of		@&lt;NOM-OF %N&lt; PREP
20	the	the	det:&gt;22	@DN&gt; %&gt;N DET
21	DNA-binding	dna-binding	attr:&gt;22	@A&gt; %&gt;N N NOM SG
22	activity	activity	pcomp:&gt;19	@&lt;P %NH N NOM SG
23	of	of	mod:&gt;22	@&lt;NOM-OF %N&lt; PREP
24	MEF2	mef2	pcomp:&gt;23	@&lt;P %NH N NOM SG
25	.     .
</fdg>
</example>
<example src="EMBO" no="4">
<text>
This G:C base pair is also the strongest determinant in the sequence selection experiment, which led to the identification of the BRE (Lagrange et al., 1998).

</text>
       <arg n="0">the sequence selection experiment
</arg>
       <arg n="1">the identification of the BRE
</arg>
<fdg>
1	This	this	det:&gt;4	@DN&gt; %&gt;N DET DEM SG
2	G:C	g:c	attr:&gt;3	@A&gt; %&gt;N N NOM SG
3	base	base	attr:&gt;4	@A&gt; %&gt;N N NOM SG
4	pair	pair	subj:&gt;5	@SUBJ %NH N NOM
5	is	be		@+FMAINV %VA V PRES SG3
6	also	also	meta:&gt;5	@ADVL %EH ADV
7	the	the	det:&gt;9	@DN&gt; %&gt;N DET
8	strongest	strong	attr:&gt;9	@A&gt; %&gt;N A SUP
9	determinant	determinant	comp:&gt;5	@PCOMPL-S %NH N NOM SG
10	in	in	loc:&gt;5	@ADVL %EH PREP
11	the	the	det:&gt;14	@DN&gt; %&gt;N DET
12	sequence	sequence	attr:&gt;13	@A&gt; %&gt;N N NOM SG
13	selection	selection	attr:&gt;14	@A&gt; %&gt;N N NOM SG
14	experiment	experiment	pcomp:&gt;10	@&lt;P %NH N NOM SG
15	,	,
16	which	which	subj:&gt;17	@SUBJ %NH &lt;Rel&gt; PRON WH NOM
17	led	lead	mod:&gt;14	@+FMAINV %VA V PAST
18	to	to	ha:&gt;17	@ADVL %EH PREP
19	the	the	det:&gt;20	@DN&gt; %&gt;N DET
20	identification	identification	pcomp:&gt;18	@&lt;P %NH N NOM SG
21	of	of	mod:&gt;20	@&lt;NOM-OF %N&lt; PREP
22	the	the	det:&gt;23	@DN&gt; %&gt;N DET
23	BRE	bre	pcomp:&gt;21	@&lt;P %NH ABBR NOM SG
24	(	(
25	Lagrange	lagrange	main:&gt;24	@APP %NH N NOM SG
26	et	et		@CC %CC CC
27	al.	al.		@APP %NH ABBR NOM SG	@A&gt; %&gt;N ABBR NOM SG	@&lt;P %NH ABBR NOM SG	@NH %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG	@ADVL %EH ABBR NOM SG
28	,	,
29	1998	1998		@NH %NH NUM CARD	@&lt;P %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
30	)	)
31	.     .
</fdg>
</example>
<example src="EMBO" no="5">
<text>
These data suggest that phosphorylation of the MuSK NPXY site leads to recruitment of a phosphotyrosine-binding domain-containing protein that functions to stimulate phosphorylation and clustering of AchRs.

</text>
       <arg n="0">phosphorylation of the MuSK NPXY site
</arg>
       <arg n="1">recruitment of a phosphotyrosine-binding domain-containing protein
</arg>
<fdg>
1	These	this	det:&gt;2	@DN&gt; %&gt;N DET DEM PL
2	data	data	subj:&gt;3	@SUBJ %NH N NOM
3	suggest	suggest	main:&gt;0	@+FMAINV %VA V PRES
4	that	that	pm:&gt;11	@CS %CS CS
5	phosphorylation	phosphorylation	subj:&gt;11	@SUBJ %NH N NOM SG
6	of	of	mod:&gt;5	@&lt;NOM-OF %N&lt; PREP
7	the	the	det:&gt;10	@DN&gt; %&gt;N DET
8	MuSK	musk	attr:&gt;9	@A&gt; %&gt;N N NOM SG
9	NPXY	npxy	attr:&gt;10	@A&gt; %&gt;N N NOM SG
10	site	site	pcomp:&gt;6	@&lt;P %NH N NOM SG
11	leads	lead	obj:&gt;3	@+FMAINV %VA V PRES SG3
12	to	to	ha:&gt;11	@ADVL %EH PREP
13	recruitment	recruitment	pcomp:&gt;12	@&lt;P %NH N NOM SG
14	of	of	mod:&gt;13	@&lt;NOM-OF %N&lt; PREP
15	a	a	det:&gt;16	@DN&gt; %&gt;N DET SG
16	phosphotyrosine	phosphotyrosine	pcomp:&gt;14	@&lt;P %NH &lt;?&gt; N NOM SG
17	-	-
18	binding	binding	attr:&gt;19	@A&gt; %&gt;N N NOM SG
19	domain-containing	domain-containing	attr:&gt;20	@A&gt; %&gt;N &lt;?&gt; A ABS
20	protein	protein	mod:&gt;16	@APP %NH N NOM SG
21	that	that	subj:&gt;22	@SUBJ %NH &lt;Rel&gt; PRON
22	functions	function	mod:&gt;20	@+FMAINV %VA V PRES SG3
23	to	to	pm:&gt;24	@INFMARK&gt; %AUX INFMARK&gt;
24	stimulate	stimulate	cnt:&gt;22	@-FMAINV %VA V INF
25	phosphorylation	phosphorylation	obj:&gt;24	@OBJ %NH N NOM SG
26	and	and	cc:&gt;25	@CC %CC CC
27	clustering	clustering	cc:&gt;25	@OBJ %NH A ABS
28	of	of	mod:&gt;27	@&lt;NOM-OF %N&lt; PREP
29	AChRs	achrs	pcomp:&gt;28	@&lt;P %NH N NOM SG
30	.     .
</fdg>
</example>
</roleset>
</predicate>
</frameset>
